Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous iPSC-derived dopaminergic progenitor cells
- Development stage
- Unknown
- Lead developer
- McLean Hospital
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intracerebral
01
Overview
An experimental autologous cell therapy for Parkinson's disease developed by Dr. Jeffrey S. Schweitzer at Massachusetts General Hospital and Dr. Kwang-Soo Kim at McLean Hospital. The therapy involves the use of patient-derived induced pluripotent stem cells (iPSCs) that are differentiated in vitro into midbrain dopaminergic progenitor cells. These cells are then surgically transplanted into the patient's putamen to replace the dopaminergic neurons that degenerate in Parkinson's disease. Because the cells are derived from the patient's own tissue, the therapy is designed to avoid immune rejection and the need for long-term immunosuppression. A Phase I pilot study published in the New England Journal of Medicine in 2020 demonstrated that the cells could be safely implanted and showed evidence of survival and clinical stabilization.
- Other names
- autologous dopaminergic cell implantationautologous midbrain dopaminergic progenitor cells
Beyond the preview
Go deeper on autologous iPSC-derived dopaminergic progenitor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous iPSC-derived dopaminergic progenitor cells.